Selected article for: "academia industry and acute respiratory"
Author: Li, Yen-Der; Chi, Wei-Yu; Su, Jun-Han; Ferrall, Louise; Hung, Chien-Fu; Wu, T.-C.
Title: Coronavirus vaccine development: from SARS and MERS to COVID-19
  • Cord-id: v9366atg
  • Document date: 2020_12_20
    • ID: v9366atg
    Snippet: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outl
    Document: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development.

    Search related documents:
    Co phrase search for related documents
    • academic institution and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • accessory protein and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • achieve work and acute respiratory: 1, 2, 3, 4
    • achieve work and acute respiratory syndrome coronavirus: 1, 2, 3, 4
    • acid vaccine and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acid vaccine and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory and addition unclear: 1, 2, 3, 4, 5, 6
    • acute respiratory and additional agent: 1, 2, 3, 4, 5, 6
    • acute respiratory and additional benefit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory and additional trial: 1, 2, 3, 4, 5
    • acute respiratory and additional viral vector: 1
    • acute respiratory syndrome coronavirus and addition unclear: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and additional agent: 1, 2, 3
    • acute respiratory syndrome coronavirus and additional benefit: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and additional trial: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and additional viral vector: 1